Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset

References

• Bjorkdahl, O., Barber, K. A., Brett, S. J., et al. 2003. Characterization of CC-chemokine receptor 7 expression on murine T-cells in lymphoid tissues. Immunology 110:170–179
   PubMedGoogle Scholar
• Bjornsson, E. 2010. Review article: Drug-induced liver injury in clinical practice. Aliment Pharmacol. Ther. 32:3–13
   PubMed Web of Science ®Google Scholar
• Bowen, D. G., Mccaughan, G. W., and Bertolino, P. 2005. Intrahepatic immunity: A tale of two sites? Trends Immunol. 26:512–517
   PubMed Web of Science ®Google Scholar
• Chao, C. C., Jensen, R., and Dailey, M. O. 1997. Mechanisms of L-selectin regulation by activated T-cells. J. Immunol. 159:1686–1694
   PubMed Web of Science ®Google Scholar
• Clarke, J. B., Maggs, J. L., Kitteringham, N. R., and Park, B. K. 1990. Immunogenicity of amodiaquine in the rat. Int. Arch. Allergy Appl. Immunol. 91:335–342
   PubMedGoogle Scholar
• Clarke, J. B., Neftel, K., Kitteringham, N. R., and Park, B. K. 1991. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int. Arch. Allergy Appl. Immunol. 95:369–375
   PubMedGoogle Scholar
• De Valle, M. B., Av Klinteberg, V., Alem, N., et al. 2006. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol. Ther. 24:1187–1195
   PubMed Web of Science ®Google Scholar
• Foureau, D. M., Walling, T. L., Kleiner, D. E., et al. 2012. Profiles of leukocytes infiltrating livers of subjects with drug-induced liver injury (DILI). Hepatology 56:596A (Abstract #827)
   Google Scholar
• Hatton, C. S., Peto, T. E., Bunch, C., et al. 1986. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1:411–414
   PubMed Web of Science ®Google Scholar
• Johnson, P., and Ruffell, B. 2009. CD44 and its role in inflammation and inflammatory diseases. Inflamm. Allergy Drug Targets 8:208–220
   PubMedGoogle Scholar
• Koo, G. C., Dumont, F. J., Tutt, M., et al. 1986. The NK-1.1− mouse: A model to study differentiation of murine NK cells. J. Immunol. 137:3742–3747
   PubMedGoogle Scholar
• Lang, P. A., Lang, K. S., Xu, H. C., et al. 2012. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc. Natl. Acad. Sci. USA 109:1210–1215
   PubMedGoogle Scholar
• Larrey, D., Castot, A., Pessayre, D., et al. 1986. Amodiaquine-induced hepatitis. A report of seven cases. Ann. Int. Med. 104:801–803
   PubMed Web of Science ®Google Scholar
• Li, X. Q., Bjorkman, A., Andersson, T. B., et al. 2002. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: A new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300:399–407
   PubMed Web of Science ®Google Scholar
• Lobach, A., and Uetrecht, J. 2014. Involvement of myeloperoxidase and NADPH oxidase in the covalent binding of amodiaquine and clozapine to neutrophils: Implications for drug-induced agranulocytosis. Chem. Res. Toxicol. 27:699–709
   PubMed Web of Science ®Google Scholar
• Lucena, M. I., Andrade, R. J., Kaplowitz, N., et al. 2009. Phenotypic characterization of idiosyncratic drug-induced liver injury: Influence of age and sex. Hepatology 49:2001–2009
   PubMed Web of Science ®Google Scholar
• Maggs, J. L., Kitteringham, N. R., Breckenridge, A. M., and Park, B. K. 1987. Autoxidative formation of a chemically-reactive intermediate from amodiaquine, a myelotoxin and hepato-toxin in man. Biochem. Pharmacol. 36:2061–2062
   PubMed Web of Science ®Google Scholar
• Maggs, J. L., Tingle, M. D., Kitteringham, N. R., and Park, B. K. 1988. Drug-protein conjugates– XIV. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man. Biochem. Pharmacol. 37:303–311
   PubMed Web of Science ®Google Scholar
• Masson, M. J., Carpenter, L. D., Graf, M. L., and Pohl, L. R. 2008. Pathogenic role of natural killer T- and natural killer cells in acetaminophen-induced liver injury in mice is dependent on the presence of dimethyl sulfoxide. Hepatology 48:889–897
   PubMed Web of Science ®Google Scholar
• Metushi, I. G., Nakagawa, T., and Uetrecht, J. 2012. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: Humans are more like mice than rats. Chem. Res. Toxicol. 25:2567–2576
   PubMed Web of Science ®Google Scholar
• Metushi, I. G., Sanders, C., Lee, W. M., and Uetrecht, J. 2013. Detection of anti-isoniazid and anti-cyp antibodies in patients with isoniazid-induced liver failure. Hepatology 59:1084–1093
   Web of Science ®Google Scholar
• Metushi, I. G., and Uetrecht, J. (2013). Isoniazid-induced liver injury and immune response in mice. J. Immunotoxicol. (Epub ahead of print)
   Google Scholar
• Mishra, S. K., Singh, P., and Rath, S. K. 2011. A study of toxicity and differential gene expression in murine liver following exposure to anti-malarial drugs: Amodiaquine and sulphadoxine-pyrimethamine. Malaria J. 10:109
   PubMedGoogle Scholar
• Neftel, K. A., Woodtly, W., Schmid, M., et al. 1986. Amodiaquine induced agranulocytosis and liver damage. Br. Med. J. 292:721–723
   PubMed Web of Science ®Google Scholar
• Ng, W., Lobach, A. R., Zhu, X., et al. 2012. Animal models of idiosyncratic drug reactions. Adv. Pharmacol. 63:81–135
   PubMedGoogle Scholar
• Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:252–264
   PubMed Web of Science ®Google Scholar
• Pure, E., and Cuff, C. A. 2001. A crucial role for CD44 in inflammation. Trends Mol. Med. 7:213–221
   PubMed Web of Science ®Google Scholar
• Rouveix, B., Coulombel, L., Aymard, J. P., et al. 1989. Amodiaquine-induced immune agranulocytosis. Br. J. Hematol. 71:7–11
   PubMed Web of Science ®Google Scholar
• Russo, M. W., Galanko, J. A., Shrestha, R., et al. 2004. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transplant. 10:1018–1023
   PubMed Web of Science ®Google Scholar
• Sallusto, F., Geginat, J., and Lanzavecchia, A. 2004. Central memory and effector memory T-cell subsets: Function, generation, and maintenance. Annu. Rev. Immunol. 22:745–763
   PubMed Web of Science ®Google Scholar
• Senior, J. R. 2007. Drug hepatotoxicity from a regulatory perspective. Clin. Liver Dis. 11:507–524
   PubMedGoogle Scholar
• Sgro, C., Clinard, F., Ouazir, K., et al. 2002. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 36:451–455
   PubMed Web of Science ®Google Scholar
• Shimizu, S., Atsumi, R., Itokawa, K., et al. 2009. Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice. Arch. Toxicol. 83:701–707
   PubMed Web of Science ®Google Scholar
• Siegelman, M. H., Degrendele, H. C., and Estess, P. 1999. Activation and interaction of CD44 and hyaluronan in immunological systems. J. Leukocyte Biol. 66:315–321
   PubMed Web of Science ®Google Scholar
• Singer, A. J., and Clark, R. A. 1999. Cutaneous wound healing. New Engl. J. Med. 341:738–746
   PubMed Web of Science ®Google Scholar
• Tian, Z., Chen, Y., and Gao, B. 2013. Natural killer cells in liver disease. Hepatology 57:1654–1662
   PubMed Web of Science ®Google Scholar
• Tujios, S., and Fontana, R. J. 2011. Mechanisms of drug-induced liver injury: From bedside to bench. Nat. Rev. Gastroenterol. Hepatol. 8:202–211
   PubMed Web of Science ®Google Scholar
• Uetrecht, J. 2009. Immunoallergic drug-induced liver injury in humans. Sem. Liver Dis. 29:383–392
   PubMed Web of Science ®Google Scholar
• Watkins, P. B. 2005. Idiosyncratic liver injury: Challenges and approaches. Toxicol. Pathol. 33:1–5
   PubMed Web of Science ®Google Scholar
• White, N. J., Looareesuwan, S., Edwards, G., et al. 1987. Pharmacokinetics of intravenous amodiaquine. Br. J. Clin. Pharmacol. 23:127–135
   PubMed Web of Science ®Google Scholar
• Yang, S., Liu, F., Wang, Q. J., et al. 2011. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T-lymphocytes. PLoS One 6:e22560
   PubMed Web of Science ®Google Scholar
• Ziegler, S. F., Ramsdell, F., and Alderson, M. R. 1994. The activation antigen CD69. Stem Cells 12:456–465
   PubMed Web of Science ®Google Scholar